

ASH Annual Meeting 2019

Plenary Scientific Session

- [Erythoferrone Regulates Bone Remodeling in \$\beta\$ -Thalassemia](#)
Melanie Castro-Mollo, MS; Marc Ruiz Martinez, PhD; Maria Feola, BSc, MSc; Anisa Azatovna Gumerova, MD; Tony Yuen, PhD; Mone Zaidi, MD, PhD; Yelena Ginzburg, MD

Oral Presentations (11)

Unless otherwise indicated, only Mount Sinai authors are listed below. Presenting author is bolded.

- [MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor \(BETi\), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis](#)
John Mascarenhas, MD; Marina Kremyanskaya; Ronald Hoffman, MD
- [Activated but Not Quiescent Hematopoietic Stem Cells Rely Readily on Glycolysis As Their Main Source of Energy](#)
Tasleem Arif, PhD; Raymond Liang, PhD; Maio Lin, Msc; Vijay Menon, PhD; Saghi Ghaffari, PhD, MD
- [Lysosomal Activation Is Required for Priming of Quiescent Hematopoietic Stem Cells](#)
Tasleem Arif, PhD; Raymond Liang, PhD; Maio Lin, Msc; Svetlana Kalmikova, Msc; Artem Kasianov, PhD; Dmitri Papatsenko, PhD; Saghi Ghaffari, PhD, MD
- [Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin](#)
Bridget Marcellino, MD, PhD; Min Lu, PhD, MD; Emmanuelle Verger, PhD; Meenakshi Mehrotra, PhD; Jane Houldsworth, PhD; Michael Rossi, PhD; John Mascarenhas, MD; Ronald Hoffman, MD
- [The MAGIC Algorithm Probability \(MAP\): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease](#)
Hrishikesh Srinagesh, BA; Umut Ozbek, PhD; Urvi Kapoor, MD; Mina D. Aziz, MD; Kaitlyn Ben-David; Aaron Etra, MD; Matthew Hartwell, MD; Steven Kowalyk; Jung-Yi Lin, MS; Hannah Major-Monfried, MD, MSCR; George Morales; Jay Shah, MD; Keith Sigel, MD, PhD; Rachel Young; John E. Levine, MD, MS; James L. M. Ferrara, MD, DSc
- [Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera](#)
Maria Feola, BSc, MSc; Daniel Moskop; Nada Terra; Ronald Hoffman, MD; Yelena Ginzburg, MD
- [Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma \(R/R MM\), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset](#)
Enrique Zudaire, PhD (Janssen R&D); Deepu Madduri, MD; Sundar Jagannath, MBBS

- [Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma \(DLBCL\)](#)
Lale Kostakoglu, MD, MPH
- [Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen \(BCMA\), in Patients with Relapsed and/or Refractory Multiple Myeloma \(R/R MM\)](#)
Deepu Madduri, MD; Sundar Jagannath, MBBS
- [A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA](#)
Lale Kostakoglu, MD, MPH
- [Phase II Study of Oral Rigosertib Combined with Azacitidine \(AZA\) As First Line Therapy in Patients \(Pts\) with Higher-Risk Myelodysplastic Syndromes \(HR-MDS\)](#)
Shyamala C. Navada, MD

Poster Presentations (28)

Only presenting authors are listed below.

- [A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain \(AL\) Amyloidosis](#)
Shyamala C. Navada, MD
- [Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update](#)
Ajai Chari, MD
- [Comparative Effectiveness of Triplets Containing Bortezomib \(V\), Carfilzomib \(K\), or Ixazomib \(I\) Combined with a Lenalidomide and Dexamethasone Backbone \(Rd\) in Patients with Relapsed/Refractory Multiple Myeloma \(RRMM\) in Routine Care in the United States \(US\)](#)
Ajai Chari, MD
- [Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell \(CAR-T\) Therapy](#)
Ajai Chari, MD
- [Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma \(RRMM\)](#)
Ajai Chari, MD

- [Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy](#)
Hearn Jay Cho, MD, PhD
- [Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies](#)
John Mascarenhas, MD
- [A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma](#)
Alessandro Lagana, PhD
- [The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase \(MPN-BP\) Stem Cells](#)
Xiaoli Wang, MD, PhD
- [Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms \(MPNs\)](#)
Joseph Tripodi, PhD
- [High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment](#)
Hearn Jay Cho, MD, PhD
- [Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide \(CC-220\) Treated Relapsed/Refractory Multiple Myeloma Patients](#)
Oliver Van Oekelen, MD, MSc
- [Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance](#)
Larysa Sanchez, MD
- [Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database](#)
Lukas Ronner
- [Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients](#)
Jessica Caro, MD
- [Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality](#)
Giulia Petrone, MD, MBBS
- [The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor \(RLR\) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome](#)
Richa Rai, PhD

- [Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes \(MDS\)](#)
Lewis R. Silverman, MD
- [A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells](#)
Min Lu, PhD, MD
- [Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms](#)
Bridget Marcellino, MD, PhD
- [The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis](#)
Leonard Naymagon, MD
- [Distinct Mechanisms Underlying the Ex Vivo Expansion of Human Cord Blood Stem Cells with Different Strategies Currently Used for Allogeneic Transplantation](#)
Luena Papa, PhD
- [Etiologies and Predictors of 30-Day Readmission in Patients Undergoing Induction Chemotherapy for Acute Myeloid Leukemia](#)
Shivani Handa, MBBS
- [Utility of Thrombophilia Testing in Portal Vein Thrombosis in a Large Single Institutional Cohort](#)
Douglas Tremblay, MD
- [The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden](#)
John Mascarenhas, MD
- [Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss](#)
Xiaochuan Yang
- [Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells](#)
Xiaoli Wang, MD, PhD
- [Role of Exosomes in Hepcidin Regulation in \$\beta\$ -Thalassemia](#)
Marc Ruiz Martinez, PhD